EUVIMEDEUVIMED entdecken
Crossref

Constructing a Ready-to-Use mRNA Vaccine Delivery System for the Prevention of Influenza A virus, Utilizing FDA-Approved Raw Materials

Yuyan Zhang, Xinyu Zhuang, Yingying Hu, Jie Chen iD, Kai Hao, Zhaohui Tang, Mingyao Tian, Huayu Tian iD, Ningyi Jin, Xuesi Chen iD

Biomacromolecules · 2024

DOI: 10.1021/acs.biomac.4c00365 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomacromolecules, 2024. Verfasst von Yuyan Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun 130022, China. Hauptthemen laut MEDLINE: Influenza Vaccines, Influenza A Virus, H1N1 Subtype. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Innovation Laboratory for Sciences and Technologies of Energy Materials of Fujian Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Messenger ribonucleic acid (mRNA) vaccines, serving as a rapid and easily scalable emergency preventive measure, have played a pivotal role in preventing infectious diseases. The effectiveness of mRNA vaccines heavily relies on the delivery carrier, but the current market options are predominantly lipid nanoparticles. Their intricate preparation process and high transportation costs pose challenges for widespread use in remote areas. In this study, we harnessed FDA-approved polymer PLGA and lipid components widely employed in clinical experiments to craft a ready-to-use mRNA vaccine delivery system known as lipid-polymer hybrid nanoparticles (LPP). Following formulation optimization, the PDCD nanoparticles emerged as the most effective, showcasing exceptional mRNA delivery capabilities both in vitro and in vivo. Loading PDCD nanoparticles with mRNA encoding the H1N1 influenza virus HA antigen-fused M2e peptide enabled the successful induction of M2e-specific antibodies and T cell immune responses in immunized mice. After three rounds of vaccine immunization, the mice demonstrated weight recovery to normal levels and maintained a survival rate exceeding 80% following an encounter with the H1N1 influenza virus. The innovative mRNA delivery system that we designed demonstrates outstanding effectiveness in preventing infectious diseases, with the potential to play an even more significant role in future clinical applications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Influenza VaccinesInfluenza A Virus, H1N1 SubtypeAnimalsMiceNanoparticlesmRNA VaccinesMice, Inbred BALB CFemaleOrthomyxoviridae InfectionsRNA, MessengerHumansInfluenza, HumanUnited StatesLipids

Substanzen

Influenza VaccinesmRNA VaccinesRNA, MessengerLipids

Autor:innen und Institutionen

  • Key Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun 130022, China.
  • School of Applied Chemistry and Engineering, University of Science and Technology of China, Hefei 230026, China.
  • Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun 130122, China.
  • State Key Laboratory of Physical Chemistry of Solid Surfaces, College of Chemistry and Chemical Engineering, Xiamen University, Xiamen 361005, China.
  • Innovation Laboratory for Sciences and Technologies of Energy Materials of Fujian Province (IKKEM), Xiamen 361005, China.

ORCID-Profile: Jie Chen, Huayu Tian, Xuesi Chen

Förderung

  • National Key Research and Development Program of China
  • National Natural Science Foundation of China
  • Innovation Laboratory for Sciences and Technologies of Energy Materials of Fujian Province

Zitieren

APA

Zhang, Y., Zhuang, X., Hu, Y., Chen, J., Hao, K., Tang, Z., Tian, M., Tian, H., Jin, N., & Chen, X. (2024). Constructing a Ready-to-Use mRNA Vaccine Delivery System for the Prevention of Influenza A virus, Utilizing FDA-Approved Raw Materials. Biomacromolecules. https://doi.org/10.1021/acs.biomac.4c00365

Vancouver

Zhang Y, Zhuang X, Hu Y, Chen J, Hao K, Tang Z, et al. Constructing a Ready-to-Use mRNA Vaccine Delivery System for the Prevention of Influenza A virus, Utilizing FDA-Approved Raw Materials. Biomacromolecules. 2024. doi:10.1021/acs.biomac.4c00365

BibTeX
@article{Zhang2024,
  author = {Zhang, Yuyan and Zhuang, Xinyu and Hu, Yingying and Chen, Jie and Hao, Kai and Tang, Zhaohui and Tian, Mingyao and Tian, Huayu and Jin, Ningyi and Chen, Xuesi},
  title = {Constructing a Ready-to-Use mRNA Vaccine Delivery System for the Prevention of Influenza A virus, Utilizing FDA-Approved Raw Materials},
  journal = {Biomacromolecules},
  year = {2024},
  doi = {10.1021/acs.biomac.4c00365}
}
Kostenlos starten →